Posted by: Audrey Erbes | July 26, 2015

Sharply Rising Costs of Generics Now a Concern

Sharply Rising Costs of Generics a Concern

Another aspect of the pricing paradigm shift is the switch to generics from branded products to save costs for care of Medicare and Medicaid patients. 80% of these latter groups are treated with much lowe- priced generics, but that may be changing as generic drug prices have been increasing. Ten percent of generic drugs have doubled more recently.

For years, PBMs have used their formularies to encourage patients to choose generic drugs by including all generics in the bottom, or lowest out-of-pocket cost, formulary tier,” says Anna Goldbeck, a principal in the National Pharmacy Practice at Buck Consultants at Xerox. “Some PBMs are reacting to the rising cost of generics by creating new tiers that require members to pay higher copayments for ‘non-preferred’ generic drugs.”

Goldbeck says factors driving price increases for generics include:

  • Consolidation among generic drug companies;
  • Shortage of raw materials;
  • Supply and demand; and
  • Regulatory issues

The U.S. Department of Health and Human Services (HHS) is now investigating the sharp rise in generic pricing and associated increases to Medicaid over the past decade. They are guaging these rising generic drug prices by comparing price increases between 2005 and 2014 against the rate of inflation. Senators want generic manufacturers to pay a rebate to Medicaid when drug rates rise faster than the rate of inflation, a provision that’s currently in place for brand-name drugs.

Highlights of Upcoming Life Science Events in the Bay Area

  • Bio2Device Group, Tuesday Morning, July 28, 2015; Topic: “A Medical Device Startup’s Obstacle Course – how Benvenue Medical is overcoming the challenges to bring new spine technology to the marketplace;” Speaker: Jeff Emery, Senior Director of R&D, Benvenue Medical :
  • GGPF, Tuesday Evening, July 28, 2015; Topic: “Shape-Persistent and Self-Healing Polymers Enabled by Efficient Chemistries;” Speaker: Prof. Yan Xia, Dept. Of Chemistry, Stanford University
  • HBA Supper Club, Tuesday Evening, July 28, 2015; Sheila Babnis, global business lead, innovation, Genentech will host an evening of networking and dinner.
  • WIB-San Francisco Bay Area, Thursday Evening, July 30, 2015; Event: Social at Cantor Arts Center

You can download complete details for the above and other meetings through December by right clicking on Audreys Picks July 26, 2015. You can also download this week’s listing of jobs– JobsThatCrossedMyDeskThrough July 26, 2015on the same site.

Note that I am not able to send my blog and lists directly to you as I did for over 10 years. You can access them by reading my weekly blog and downloading my lists at https://audreysnetwork.wordpress.com/

Audrey

Posted by: Audrey Erbes | July 19, 2015

What If Users Set Drug Prices?

Shifting Sands on Drug Pricing

What if health care insurers and payers set the price they would pay for drugs for their clients based on their value calculations? Until this past year such an occurrence seemed impossible or improbable. Short of a branded drug being genericized, patients had no recourse but to pay the company set prices. Some patients who could access drugs outside the U.S. or bought drugs online are able to get a lower price but also risk getting ineffective drugs.

What will pharma companies do in reaction to all the talk of others setting their prices? This will certainly happen in some form in the high priced cancer drug arena based on the momentum underway and public opinion supporting a change. What do you think?

Upcoming Life Science Events in the Bay Area The Week of July 20, 2015

  • Bio2Device Group, Tuesday Morning, July 21, 2015, Topic: “Dye-less or OCT Angiography for Diagnosis and Management of Ocular Diseases;” Speaker: Utkarsh Sharma, Project Team Leader / Staff Scientist, Carl Zeiss Meditec
  • BioScience Forum, Wednesday Evening, July 22, 2015; Topic: “Addressing the Challenges of Innovation Through Proactive Collaboration and Investment;”Speaker: Thorsten Melcher, Ph.D., Senior Director, New Ventures, Johnson & Johnson Innovation

You can download complete details for the above and other meetings through December by right clicking on Audreys Picks July 19, 2015.

Hope you are enjoying the summer and, especially, the rain that has appeared in some parts of the state.

Note that I am not able to send my blog and lists directly to you as I did for over 10 years. You can access them by reading my weekly blog and downloading my lists at https://audreysnetwork.wordpress.com/

Audrey

Hope you had a relaxing and enjoyable holiday. I’ve been out of town with European visitors since the 4th but am providing the list of upcoming meetings in the Bay Area as well as Jobs That Crossed My Desk. Note that I am only providing my lists on my blog found at https://audreysnetwork.wordpress.com/ so you must go to the blog to receive them.

A reminder that it’s important to build and maintain a vibrant network. Being listed on Linked In is not enough by itself. You really need to have in person contacts to provide support when you are considering changing positions. This means committing time to networking as well as attending programs where you can meet new contacts and also learn new material to keep your skills up-to-date.

Upcoming Life Science Meetings in the Bay Area

  • Bio2Device Group, Tuesday Evening, July 14, 2015, Topic: “Six Ways to Fail as an Entrepreneur,” Speaker: Tom Duerig, Founder and CTO, Nitinol Devices and Components
  • NCC ACRP, Thursday Evening, July 16, 2015, Event: Association of Clinical Research Professionals (ACRP) Networking Event –
  • CABS Science Workshop, Thursday, July 16, 2015, Event: “Targeted Drug Delivery, Not Just ADCs. How Far Are We from the “Magic Bullet”?”

You can download Audreys Picks July 12, 2015 with complete details on the above and other meetings and conferences through Dec. 2015 by right clicking on the highlighted titles. JobsThatCrossedMyDeskThrough July 12, 2015 is also provided.

Notice:

I am currently no longer able to send my weekly blogs and lists to individuals due to my provider’s ruling that I appear to be sending spam. Until I work this out, I will only be posting the blog and lists to my website https://audreysnetwork.wordpress.com/ and the industry linked in groups to which I post. I apologize for this. I will notify you as this situation develops.

Audrey

Posted by: Audrey Erbes | June 28, 2015

Supreme Court ACA Decision Maintains Coverage to 6.5 Million

Impact of Supreme Court’s Affordable Care Act Decision

ObamaCare appears to have survived a possible crippling impact from a decision by the Supreme Court with regard to interpretation of whether citizens could receive assistance under health care exchanges in states established by Federal government. The decision of 6 to 3 with the majority opinion written by Justice Roberts would seem to “seal the deal” but some conservative politicians are still talking about undoing the Affordable Care Act.

Commentators say the Republicans were rescued by this decision as they would have inherited a situation where they would need to develop solution to correct removal of health care from 6 and a half million Americans who qualified earlier.

Industry stocks responded favorably to the outcome and many citizens breathed a sigh of relief. Those who were without insurance for many years feared losing their access available these past several years under ACA. They were especially relieved.

Upcoming Meetings in Bay Area the Weeks of June 28 and July 6

  • Bio2Device Group, Tuesday Morning, June 30, 2015; “Development of a novel targeted antibody fusion protein as a new generation cancer therapeutic;” Speaker: Rathin Das, CEO, Synergys Biotherapeutics
  • Qb3 Entrepreneurship Seminar, Tuesday Mid Day, June 30, 2015; Topic: “Empowering Consumer Health Through Technological Innovation & Partnerships;” Speakers: Chris Chu, Director of Investments and Tejash Shah, Director of Strategy and Business Development Samsung Strategy and Innovation Center
  • Palo Alto AWIS, Tuesday Evening, June 30, 2015; Topic: “Pave Your Career Path by Getting Involved with AWIS” and ice cream social
  • Bio2Device Group, July 7th—No Meeting

You can download Audreys Picks June 28, 2015 with complete details on the above and other meetings and conferences through Dec. 2015 by right clicking on the highlighted titles. JobsThatCrossedMyDeskThrough June 28 final, 2015 is also provided.

Notice:

I am currently no longer able to send my weekly blogs and lists to individuals due to my provider’s ruling that I appear to be sending spam. Until I work this out, I will only be posting the blog and lists to my website https://audreysnetwork.wordpress.com/ and the industry linked in groups to which I post. I apologize for this. I will notify you as this situation develops.

Have a great holiday weekend and I’ll be back on July 12.

Audrey

Some New Ideas for Cancer Drug Pricing

Memorial Sloan Kettering Cancer Center doctors have come up with a cancer drug pricing calculator called DrugAbacus in a challenge to the pharmaceutical industry to come up with a more rational pricing formula. Their calculator suggests giving increases and reductions to a cancer drug’s value, and therefore, its pricing according to the following factors:

  • How much do patients benefit from the treatment?
  • How difficult are the treatment’s side effects?
  • Is the treatment for a rare disease?
  • Does the treatment address a large public health burden?
  • Is the treatment using a novel or new mechanism?
  • Did the treatment cost a lot to discover or develop?

You can find more about this at http://www.drugabacus.org/

You can read a full description of the above action in a Wall Street Journal article entitled “How Much Should Cancer Drugs Cost?” found at http://www.wsj.com/articles/how-much-should-cancer-drugs-cost-1434640914?KEYWORDS=peter+bach

Dr. Peter Bach led the group to come up with this suggested approach to pricing. In an interview, Dr. Bach said prices for many new cancer drugs don’t reflect their value to doctors and patients. “Right now, manufacturers have total price control, and total control of prices has led to irrational pricing behaviors,” he said.”

Daniel Goldstein, a medical oncologist at Winship Cancer Institute of Emory University is quoted in the same article as saying, “Currently cancer drug prices aren’t linked to the benefit they provide. They’re currently priced on what the market can bear, which is an unsustainable system.”

It will be interesting to hear Pharma responses to this challenge to their pricing methods for cancer drugs.

Contractors at Real Endpoints, a drug-cost analysis firm, and engineers from the software firm NetQuarry helped develop the Drug Abacus.

Upcoming Bay Area Meetings This Coming Week

  • GGPF, Monday Evening, June 22, 2015; Event: Dinner lecture: “Materials for Enabling Nanomanufacturing,” Speaker: Alshakim Nelson, University of Washington & IBM Almaden Research Labs
  • Bio2Device Group, Tuesday Morning, June 23, 2015; Topic: “Sports Analytics & the Future of Wearables,” Speaker: Avery Lu, Co-Founder & CM), Palo Alto Scientific
  • Rosenman Institute, Wednesday Afternoon, June 24, 2015; Topic: “How Precision Medicine is Transforming Medical Devices;” Speakers: Zachary Bogue, Co-Managing Partner, Data Collective; Edward Chang, MD, Professor in Residence, Neurological Surgery & Phy6siology, UCSF; Christine Leong Connors, Managing Director, JPMorgan Chase; Eric David, MD, JD, Chief Strategy Officer, Organovo; Regis Kelly, PhD, OBE, Special Advisor to the President on Innovation and Entrepreneurship, University of California, and Director, QB3; Richard Klausner, MD, Senior VP and CMO, Illumina; Juan-Pablo Mas, Partner, Action Potential Venture Capital; Casey McGlynn, Partner, Wilson Sonsini Goodrich & Rosati; Campbell Rogers, MD, CMO, Heartflow; Bruce Rosengard, MD, PhD, CTO, Global Surgery, Johnson & Johnson
  • BioScience Forum, Wednesday Evening, June 24, 2015; Topic: “The CRISPR/Cas9 Genome Editing Revolution;” Speaker: Jacob Corn, Ph.D., Scientific Director, Innovative Genomics Initiative, UC Berkeley
  • Band of Angels, Thursday Afternoon, June 25, 2015; Event: “Mentor Day for Startups”
  • The 23rd Annual Medical Device Dinner and Next Day Conference, Thursday and Friday, June 25-26, 2015
  • Medical Device Dinner And Interview with Steve Blank, Thursday June 25, 2015, 6:00 – 9:00 pm, Location: Sharon Heights Golf and Country Club, 2900 Sand Hill Road, Menlo Park, CA
  • 23rd Annual Medical Device Conference, Date and Time: June 26, 2015, 8:00 am – 5:00 pm, Location: Palace Hotel 2 New Montgomery Street San Francisco, CA

You can download Audreys Picks June 21, 2015 with complete details on the above and other meetings and conferences through Dec. 2015 by right clicking on the highlighted titles. JobsThatCrossedMyDeskThrough June 21, 2015 is also provided.

Audrey

Since the Congress is stalled due to extreme partisanship and brinksmanship by a minority of even one at times, the Supreme Court has stepped into the vacuum on issue of the Affordable Health Care Act. The lawsuit comes down to the interpretation of just four words according to those who support it. The outcome of possibly trashing the entire act lies with five conservative judges. In a June 9th article covering statements by President Obama as to why the Court should not kill the Act in front of audience of health care administrators, the Washington Post quotes Obama ““Five years in, what we are talking about is no longer just a law.” () “It’s no longer just a theory. It isn’t even just about the Affordable Care Act or Obamacare,” he said. “This is now part of the fabric of how we care for one another. This is health care in America.”

The intent of the act was to provide affordable health care to all Americans. Yet now the future of the act hangs on the interpretation of four words in the bill that were overlooked in the drafting. While typically such problems with text are resolved administratively, challengers to the law have chosen litigation which has now risen to Supreme Court level. I don’t believe that this law should be taken down in its entirety over the interpretation of just four words any more than I believe that Medicare would be taken down over four words. Some would say that there will be chaos if law goes down, especially, in face of more favorable views of the act since the horror stories predicted by challengers didn’t come to pass.

The law states that tax credits will be available through so-called exchanges, or online marketplaces, “established by the State.” Since not all states established these exchanges as anticipated when the law was written, but rather the Federal government stepped in to create them, the case argues that Federal government-established exchanges should not get subsidies. Congress would have corrected this phase in more bipartisan Congress but didn’t so. Now the Supreme Court takes a shot at potentially invalidating the law which has been in effect for over 5 years and added over 7 million to those receiving health care. The administration and other proponents say the words must be read in the context of a law clearly intended to make health insurance more widely available and affordable.

The health care industry will be affected by the outcome of the decision expected this month. Once again Judge Roberts’ vote will be critical just as it was in 2012 when the law was upheld by a 5-4 vote in an opinion written by Chief Justice John Roberts.

Millions more patients funded to obtain our industry’s products means a favorable impact on revenues so it’s best for the industry if the law is upheld and subsidies are made available for lower income citizens. On moral grounds I’d like to see the U.S take its place with most Western powers who recognize that universal health care is a right of their citizens.

Upcoming Bay Area Life Science Events

  • Bio2Device Group, Tuesday Morning, June 16, 2015; Topic: “Augmenting human cognitive capabilities with IBM Watson – a way to the future through the Human-Machine communications;” Speaker: Mike Kuznetsov
  • Stanford Medical School, Wednesday Evening, June 17, 2015; Topic: “The GutCheck – an EKG for the gut;” Speaker: Steve Axelrod, CEO, G-Tech Medical
  • Deloitte and HBA, Thursday Evening, June 18, 2015; Topic: “Digital Innovations in the Healthcare Ecosystem: The Next Generation;” Speaker: Dr. Harry Greenspun, MD, director of Deloitte Center for Health Solutions
  • PBSS, Friday Afternoon, June 19, 2015; Topic: “Identification and Monitoring of Impurities and Degradants in drug substances and drug products: Regulatory Requirements, Analytical Strategies and Techniques;” Speakers: Dr. Jim Zhang, Senior Director of Quality Control, Alexza Pharmaceuticals; Dr. Maria Victoria Slva Eipe, Principal Scientist for the Attribute Sciences Department at Amgen in Thousand Oaks, CA and Dr. Christine Gu, Department of Pharmaceutical Science at Genentech

You can download Audreys Picks June 14, 2015 with complete details on the above and other meetings and conferences through Dec. 2015 by right clicking on the highlighted titles. JobsThatCrossedMyDeskThrough June 14, 2015 is also provided.

Audrey

With changing parameters on what is the best protocol for clinical trials, the question arises if patient centered trials are consistent with need for population based data needed for registration and reimbursement. Ronald Epstein and Richard Street write in their article entitled “The Values and Value of Patient-Centered Care” that “There have been concerns that patient-centered care, with its focus on individual needs, might be at odds with an evidence-based approach, which tends to focus on populations.” But proponents of evidence-based medicine now accept that a good outcome must be defined in terms of what is meaningful and valuable to the individual patient.

In the April 2015 article entitled “Endpoints in Cancer Trials: Putting Patients First,” Brad Thompson, Ph. D. makes case for change in endpoint focus for cancer trials from progression free survival (PFS) and overall survival (OS) to response rate (RR) as primary endpoint and OS as a follow-on endpoint He makes case that if industry changed to RR and the FDA accepted that for registration, there might ultimately be more drugs that can be approved boosted by more patients motivated to participate in trials.

Highlights of Upcoming Week’s Bay Area Meetings

  • East Bay AWIS, Monday Evening, June 8, 2015; Topic: “How to Use Decision Making to be a Collaborative Leader;“ Speaker: Betina Schonberger, Senior Consultant with Interaction Associates
  • Bio2Device Group, Tuesday Evening, June 9, 2015; Topic: “Why Do Women Keep Dying from Breast Cancer?: The Role of Automated Breast Ultrasound Screening (ABUS) in Early Detection;” Speakers: Dennis Meister, Global Product Director, General Imaging Ultrasound at GE Healthcare & Anupam DattaMajumdar, Vice President of Engineering for U-Systems
  • JLABS, Wednesday MidDay, June 10, 2015; Topic: “How To… Set a Regulatory Roadmap;” Speaker: Kathleen H. Gibbon, Director, Global Regulatory Affairs, Janssen Research & Development, LLC
  • Free Bioceutics Webinar, Wednesday Morning, June 10, 2015; Webinar Topic Is Pharma Leveraging the Diagnostic in Targeted Therapy Branding and Communications? “The Pharma Personalized Medicine Branding Report ‘WHO, WHAT AND WHY';” Speaker: Sanna Paakkonen, EVP, Managing Director, Bioceutics; Paul J Pfleiderer, SVP, Director, Medical Affairs, Bioceutics
  • EPPIC and CBA, Wednesday Evening, June 10, 2015; Topic: “Modern Seafarers: Navigating Life Sciences Investments and Entrepreneurship Between the US and the Far East;” Speakers: Anula Jayasuriya, MD, PhD, MBA, Co-founder of Evolvence India Life Sciences Fund;Jonathan Norris, JD, Managing Director, Healthcare Practice, Silicon Valley Bank; Mohan Uttarwar, Co-Founder & CEO, iNDx LifeCare, Inc.;Jimmy Wei, PhD, MBA, Venture Partner, KPCB, China; Chen Yu, MD, MBA, Managing Partner, Vivo Capital; Moderators: Glen Sato, JD, MBA, Partner, Cooley; Cheni Kwok, PhD, CLP, Managing Partner, Linear Dreams
  • BOLD/WIB, Thursday, June 11, 2015; Topic: “Prioritizing Gender Equity: What does it take to reach and succeed at the “C” and Board level?” Moderator: Heather Erickson is president and chief executive officer of the Life Sciences Foundation; Panelists: Laura Brege, President and CEO, Nodality, Inc.; Mark A. Goldsmith, M.D., Ph.D., President and CEO, REVOLUTION Medicines, Partner, Third Rock Ventures; Wende Hutton, General Partner, Seasoned Strategist, Canaan Partners; ; Kim Popovits, CEO and Chairman of the Board, Genomic Health; Dr. Laura Shawver, CEO, Cleave Biosciences

You can download Audreys Picks June 7, 2015 with complete details on the above and other meetings and conferences through Dec. 2015 by right clicking on the highlighted titles. JobsThatCrossedMyDeskThrough June 7, 2015 is also provided.

Advise colleagues who would like to  access my blog to go to https://audreysnetwork.wordpress.com/

Audrey

Posted by: Audrey Erbes | June 1, 2015

Is Biotech Funding About to Change? Plus Events and Jobs

There continues to be talk about status of biotech industry going forward. I found Peter Young’s article “Hot and Cold: Biotech M&A and Financial Trends” published May 26 2015 provides an excellent overview with insights into trends and need for caution. There’s been an open window for IPOs longer than usual but one needs to remember that window will eventually close and VC doors may also shut. This week’s coming events are slim due to holidays this past week

  • Bio2Device Group, Tuesday Morning, June 2, 2015, Topic: ”Harnessing Technology to Improve Customer Engagement for Medical Device;”Speakers: David Judelson & Aroon Krishna, Co-Founders, VirtuMed

You can download Audreys Picks May 31, 2015 with complete details on the above and other meetings and conferences through Dec. 2015 by right clicking on the highlighted titles. JobsThatCrossedMyDeskThrough May 31, 2015 is also provided. Audrey  

I ran across a most interesting list of suggestions for pharmaceutical industry to provide more transparency in their drug pricing similar to what the hospital industry had to do. It is inevitable that drug companies will have to be more forth right about pricing in the future due to pressures from many stakeholders. In the article “Is Pharma Ready For The Mounting Price Transparency Storm? Ken Congdon, Chief Editor, Pharmaceutical Online provides some ideas. I quote:

  1. “Be proactive— Begin gaining a granular understanding of costs at every phase of the manufacturing process (e.g. R&D, supply chain, logistics) and start packaging this data in a manner that’s fit for public consumption.\
  2. Adjust your messaging (if necessary)— If (or more likely when) your organization is required to divulge drug costs and pricing rationale, be prepared to combat push back from both federal and state legislators, as well as the general public. Be able to defend your current pricing logic with carefully prepared evidence and messaging.
  3. Look for opportunities for granular savings— Like hospitals, pharmaceutical manufacturers should immediately begin looking for ways to cut costs and eliminate waste from every phase of the drug making process in an effort to offer more competitive prices to patients without sacrificing profitability. This effort should include application of lean methodologies, organizational restructuring, and potential process automation through effective application of IT solutions. “

Highlights of This Coming Week’s Bay Area Events

  • Bio2Device Group, Tuesday Morning, May 26, 2015, Topic: “The Revolution(s) in Healthcare: from the Point of View of a Software Engineer Turned Patient,“ Speakers: Vincent Keunen, Founder and CEO & Marketing, A7 Software and Maite Grisard, Chief Marketing Officer at A7-Software
  • Palo Alto AWIS, Tuesday Evening, May 26, 2015, Topic: “Policy Dialogues: Translating Science for Decision Makers: Do you want to leverage your academic background to effect change on a governmental level?” Speaker: Alia Schoen, Ph.D, Program Manager for the ChEM-H Institute at Stanford
  • JLABS, Wednesday Mid Day, May 27, 2015, Topic: “Out of the Lab and into the Newsroom;” Speakers: Michael Fitzhugh| Staff Writer, BioWorld Today; Stephanie Lee | Senior Technology Reporter, Buzzfeed; Ron Leuty | Biotech reporter, San Francisco Business Times; Riley McDermid | Senior Breaking News Editor, BioSpace; Susan Schaeffer | Editor, BioCentury; Carin Canale-Theakston | President and Founder, Canale Communications Inc.
  • BioScience Forum, Wednesday Evening, May 27, 2015;Topic: “First in Human Experience with a Novel Inhibitor of Fatty Acid Synthase for the Treatment of Solid Tumors;” Speaker: Merdad Parsey, M.D., Ph.D., Chief Executive Officer, 3-V Biosciences
  • PBSS Workshop, Thursday Afternoon, May 28, 2015, Topic: “Preclinical Development & IND/CTA Filing: DMPK, Safety, CMC, Clinical Plans & Regulatory Issues;” Speakers: Tracy Chen, Bert Ho, Kathleen Meyer, Peter Staehr
  • QB3, Thursday Afternoon, May 28, 2015; Topic: Clinical Research In Challenging Times; Speaker: Peter Blaisdell, Formerly Executive Director, Global Study Management, Amgen
  • Biopharma Consortium Breakfast Briefing Series, Friday Morning, May 29, 2015; Topic: “Looking Forward by Glancing Back: A Review of the Current Biopharma Deals Landscape with Emerging Trends in Licensing and M&A;” Speaker: Laura Vitez, Principal Business Analyst, Thomson Reuters

You can download Audreys Picks May 24, 2015 with complete details on the above and other meetings and conferences through Dec. 2015 by right clicking on the highlighted titles. JobsThatCrossedMyDeskThrough May 24, 2015 is also provided.

Audrey

 

 

 

Posted by: Audrey Erbes | May 17, 2015

Bay Area Life Science Events for Weeks of May 17-31, 2015

It’s time for another holiday the end of the month so it’s not surprising that there are many meetings this coming week, especially, on Tuesday, May 19th. I’ve also listed meetings for the week of the 24th due to the holiday on the 25th.

Since I haven’t had any new jobs cross my desk this past week, there is no list of jobs at this time.

Bay Area Life Science Events The Next Two Weeks

  • QB3 and UCSF-Stanford CERSI, Monday Mid-day, May 18, 2015; Topic: “Therapeutic Equivalence: The Key Issue For Generic Drug Review;” Speaker: Robert Lionberger, Director of the Office of Research and Standards, Office of Generic Drugs, FDA
  • Bio2Device Group, Tuesday Morning, May 19, 2015; Topic: “Expansion into Europe – Opportunities and Challenges for U.S. Life Sciences Companies;” Speaker: Piet Weinreich, Senior Associate, Osborne Clarke
  • WIB, Tuesday Evening, May 19, 2015; Topic: “ Reimbursements: Successful Solutions to Challenges in Biotech;” Speakers: Marijke Annis (Moderator) M.S.P.H. Founder, Annis & Associates Consulting; Becky Foster, M.P.H. Managed Care and Reimbursement independent consultant; Marianne Laouri, Ph.D. Specialist leader, Deloitte Consulting; Vanessa A. Jacobsen, PharmD, Principal Liason, Health Economics and Outcomes   Research, Janssen Scientific Affairs, LLC
  • GGPF, Tuesday Evening, May 19, 2015; Topic: “Polymers Hard at Work in Your Smart Phone;”Speaker: Jeff Gotro, InnoCentrix
  • QB3, Tuesday Early Afternoon, May 19, 2015; Topic: “Turning Science Into Medicine: Working Toward Better Outcomes For Patients, Companies & Society;” Speaker: George Scangos, CEO, Biogen
  • sfAWIS, Wednesday Evening, May 20, 2015; Topic: “Managing Stress: A Mindfulness Approach;” Speaker: Anita Joubel, PhD
  • QB3, May 20, 2015 and June 9, 2015; Event: “QB3 Summer 2015 NSF SBIR Bootcamp;” Instructor: Shauna Farr-Jones, PhD, UCSF/QB3 grant writer
  • JLABS, Wednesday Mid Day, May 27, 2015; Topic: “Out of the Lab and into the Newsroom;” Speakers: (List in formation) Michael Fitzhugh, Staff Writer, BioWorld Today; Stephanie Lee | Senior Technology Reporter, Buzzfeed; Susan Schaeffer, Editor, BioCentury; Carin Canale-Theakston | President and Founder, Canale Communications Inc.
  • BioScience Forum, Wednesday Evening, May 27, 2015; Topic: “First in Human Experience with a Novel Inhibitor of Fatty Acid Synthase for the Treatment of Solid Tumors; Speaker: Merdad Parsey, M.D., Ph.D., Chief Executive Officer, 3-V Biosciences
  • PBSS Workshop, Thursday Afternoon, May 28, 2015; Topic: “Preclinical Development & IND/CTA Filing: DMPK Safety, CMC, Clinical Plans & Regulatory Issues;” Speakers: Tracy Chen, Bert Ho, Kathleen Meyer, Peter Staehr
  • QB3, Thursday Afternoon, May 28, 2015; Topic: “Clinical Research In Challenging Times;”Speaker: Peter Blaisdell, Formerly Executive Director, Global Study Management, Amgen

You can download Audreys Picks May 17, 2015 with complete details on the above and other meetings and conferences through Dec. 2015 by right clicking on the highlighted title.

Audrey

Older Posts »

Categories

Follow

Get every new post delivered to your Inbox.

Join 99 other followers